Login to Your Account

Chi-Med files NDA in China for fruquintinib in third-line CRC

By Shannon Ellis
Staff Writer

Wednesday, June 14, 2017

SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med), of Shanghai, presented at the recent American Society of Clinical Oncology meeting in Chicago full phase III data for fruquintinib, an oral VEGF inhibitor, for third-line colorectal cancer (CRC). The firm is now in the process of filing an NDA in China where there is no approved drug for third-line CRC. Chinese patients who have failed two prior chemo treatments are a step closer to a treatment that is less toxic and can add 2.7 months over current standard of care.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription